Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis - 23/08/11

Doi : 10.1016/j.tube.2007.12.001

Ida Rosenkrands ^a,^⁎ , Claus Aagaard ^a,^{^{1
K.W. and C.A. contributed equally to this work.}}, Karin Weldingh ^a,^{^{1
K.W. and C.A. contributed equally to this work.}}, Inger Brock ^a,^{^{2
Present address: Department for Clinical Microbiology, University Hospital, Hvidovre, Denmark.}}, Morten H. Dziegiel ^b, Mahavir Singh ^c,^d, Søren Hoff ^a, Pernille Ravn ^e, Peter Andersen ^a
^a Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark
^b HS Blodbank KI2034, Copenhagen University Hospital, Copenhagen, Denmark
^c Department of Genome Analysis, Helmholtz Center for Infection Research, Inhoffenstrasse 7, 38124 Braunschweig, Germany
^d LIONEX GmbH, Inhoffenstrasse 7, 38124 Braunschweig, Germany
^e Department for Clinical Microbiology, University Hospital, Hvidovre, Denmark

Corresponding author. Tel.: +4532683721; fax: +4532683035.

Summary

Forty-seven Mycobacterium tuberculosis genes from the ‘regions of difference’ RD2-7, RD9-13 and RD15 were cloned and expressed, and the purified recombinant proteins were screened for their serodiagnostic potential. Evaluation of six selected proteins in serum samples from Danish resident tuberculosis patients and healthy controls led to identification of Rv0222 as the most promising serodiagnostic antigen.

Recognition of the Rv0222 was compared with the 38kDa protein and a fusion protein of the RD1 proteins ESAT-6 and CFP10 in a serum panel from pulmonary tuberculosis (TB) patients from Uganda. The highest overall sensitivity was observed for Rv0222 compared to BCG-vaccinated non-endemic healthy controls as well as symptomatic endemic controls. Importantly, Rv0222 identified human immuno deficiency (HIV) virus-positive patients and HIV-negative patients with the same overall sensitivity.

The results emphasize the importance of cut-off values in TB endemic regions based on endemic control individuals to diagnose active TB, and identify Rv0222 as a promising new antigen for serodiagnosis of TB in both HIV-negative and HIV-positive patients.

Le texte complet de cet article est disponible en PDF.

Keywords : Antibodies, Antigens, Tuberculosis, Serology, Diagnostic test, Humoral, Recombinant, ELISA, BCG, HIV

Plan

Introduction

Materials and methods

PCR on clinical isolates

RNA isolation and RT-PCR

Database searches

Results

Screening of 47 recombinant RD proteins for recognition by sera of TB patients

Evaluation of the most promising antigens in Danish resident TB serum panel

Evaluation of Rv0222 in African TB patients with or without HIV co-infection

Detection of Rv0222 in clinical isolates and transcription of the gene

Discussion

Export

Vol 88 - N° 4

P. 335-343 - juillet 2008 Retour au numéro

Article précédent

Consequence of prior exposure to environmental mycobacteria on BCG vaccination and diagnosis of tuberculosis infection
Michelle Thom, Chris Howard, Bernardo Villarreal-Ramos, Elinor Mead, Martin Vordermeier, Jayne Hope

| Article suivant

Adverse reactions to Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species
D. Murphy, L.A.L. Corner, E. Gormley

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis - 23/08/11

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL